Department of Anesthesiology and Pain Medicine, The Ottawa Hospital, Ottawa, Canada.
Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Canada.
Diving Hyperb Med. 2022 Jun 30;52(2):126-135. doi: 10.28920/dhm52.2.126-135.
As the COVID-19 pandemic evolves, new effective treatment options are essential for reducing morbidity and mortality as well as the strain placed on the healthcare system. Since publication of our initial review on hyperbaric oxygen treatment (HBOT) for hypoxaemic COVID-19 patients, interest in HBOT for COVID-19 has grown and additional studies have been published.
For this living systematic review update the previously published search strategy (excluding Google Scholar) was adopted with an extension from 01 February 2021 to 01 April 2022. Study inclusion criteria, data extraction, risk of bias estimation and dispute resolution methods were repeated.
Two new studies enrolling 127 patients were included in this update, taking the total to eight studies with 224 patients. Both new studies were randomised controlled trials, one at moderate and one at high risk of bias. Across these eight studies, 114 patients were treated with HBOT. All reported improved clinical outcomes without observation of any serious adverse events. Meta-analysis remained unjustified given the high heterogeneity between studies and incomplete reporting.
This updated living systematic review provides further evidence on the safety and effectiveness of HBOT to treat acute hypoxaemic COVID-19 patients.
随着 COVID-19 大流行的发展，寻找新的有效治疗方法对于降低发病率和死亡率以及减轻医疗系统压力至关重要。自我们最初发表关于高压氧治疗（HBOT）治疗低氧血症 COVID-19 患者的综述以来，人们对 COVID-19 的 HBOT 治疗产生了兴趣，并且已经发表了更多的研究。
对于本次实时系统更新，我们沿用了之前发表的搜索策略（不包括 Google Scholar），并将其扩展到 2021 年 2 月 1 日至 2022 年 4 月 1 日。研究纳入标准、数据提取、偏倚风险评估和争议解决方法均重复进行。
本次更新纳入了两项新的研究，共纳入 127 名患者，总计纳入 8 项研究，共纳入 224 名患者。这两项新研究均为随机对照试验，一项为中度偏倚，一项为高度偏倚。在这八项研究中，共有 114 名患者接受了 HBOT 治疗。所有研究均报告了改善的临床结局，且未观察到任何严重不良事件。由于研究间存在高度异质性且报告不完整，Meta 分析仍不合理。
本次实时系统更新提供了更多关于 HBOT 治疗急性低氧血症 COVID-19 患者的安全性和有效性的证据。
